XML 50 R36.htm IDEA: XBRL DOCUMENT
v3.20.4

REVENUE RECOGNITION AND COLLABORATIVE ARRANGEMENTS (Details) - USD ($) $ in Thousands | 12 Months Ended |
--- | --- | ---
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2014
Revenue Recognition and Collaborative Arrangements |  |  |  |
Total net revenue | $ 336,794 | $ 261,016 | $ 261,004 |
Strategic alliance - MABA program |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Revenue recognized upon termination of contract | 10,000 |  |  |
Royalty revenue from a related party |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Total net revenue | 326,794 | 261,016 | 261,004 |
Revenue from collaborative arrangements with a related party |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Total net revenue | 10,000 | 0 | 0 |
GSK |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Total net revenue | 336,794 | 261,016 | 261,004 |
Milestone fees paid | $ 220,000 | 220,000 |  |
GSK | Long-Acting Beta2 Agonist (LABA) Collaboration |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Milestone fees paid |  |  |  | $ 220,000
Percentage of economic interest in any future payments made under the agreements | 15.00% |  |  |
GSK | Royalty revenue from a related party |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Royalties from a related party | $ 340,617 | 274,839 | 274,827 |
Less: amortization of capitalized fees paid to a related party | (13,823) | (13,823) | (13,823) |
Total net revenue | 326,794 | 261,016 | 261,004 |
GSK | RELVAR/BREO |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Royalties from a related party | $ 221,536 | 189,424 | 220,162 |
GSK | RELVAR/BREO | Long-Acting Beta2 Agonist (LABA) Collaboration |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Royalty rate for first level of annual global net sales (as a percent) | 15.00% |  |  |
Annual global sales level used to determine royalty rate | $ 3,000,000 |  |  |
Royalty rate for sales above first level of annual global net sales (as a percent) | 5.00% |  |  |
GSK | ANORO |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Royalties from a related party | $ 45,992 | 42,625 | 41,286 |
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Royalty rate for combination products (as a percent) | 6.50% |  |  |
GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Royalty rate for combination products (as a percent) | 10.00% |  |  |
GSK | TRELEGY |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Royalties from a related party | $ 73,089 | 42,790 | 13,379 |
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Royalty rate for combination products (as a percent) | 6.50% |  |  |
GSK | TRELEGY | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Royalty rate for combination products (as a percent) | 10.00% |  |  |
GSK | Revenue from collaborative arrangements with a related party | Strategic alliance - MABA program |  |  |  |
Revenue Recognition and Collaborative Arrangements |  |  |  |
Total net revenue | $ 10,000 | $ 0 | $ 0 |

X
- Definition Represents the royalty rate for combination products. + References No definition available. + Details
Name: | inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales. + References No definition available. + Details
Name: | inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement. + References No definition available. + Details
Name: | inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees. + References No definition available. + Details
Name: | inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
Namespace Prefix: | inva_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of economic interest in any future payments made under the agreements. + References No definition available. + Details
Name: | inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
Namespace Prefix: | inva_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 40 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054 + Details
Name: | us-gaap_CapitalizedContractCostAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 40 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054 + Details
Name: | us-gaap_CapitalizedContractCostGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 + Details
Name: | us-gaap_GainLossOnContractTermination
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_CollaborativeArrangementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=inva_TrelegyElliptaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |